Good News for Abbott Labs - Analyst Blog


Abbott Labs ( ABT ) recently announced encouraging initial results from a study on its ARCHITECTSTAT High Sensitive Troponin-I (hsTnI) test.

The study is being conducted by researchers at the University of Edinburgh. The initial results from the study showed that the test can help the doctors improve the diagnosis and prognosis of patients with symptoms of heart attack.

Abbott further stated in its press release that the test could be particularly helpful for women who might have different symptoms and often are under-diagnosed.  The test received CE Mark in Jan 2013. However, the test is not yet approved in the U.S., and is being used only for research purposes.

We note that Abbott Labs continues to invest in the development of next-generation instruments and other advanced technologies in its diagnostics business. In Jun 2013, Abbott Labs launched its hepatitis C virus genotyping test following approval by the U.S. Food and Drug Administration.

Abbott Labs' diagnostics business generated sales of $1.1 billion in the second quarter of 2013, up 5.3% year over year. The business is expected to post high single-digit growth in the third quarter of 2013 (excluding currency impact) driven by solid growth across all categories.

Abbott Labs is currently investing in six new system platforms across its three diagnostic businesses. We are encouraged by Abbott Labs traction in its diagnostics business and expect further momentum from new tests.

We remind investors that Abbott Labs became a diversified medical products company focusing on branded generic pharmaceutical, medical devices, diagnostic and nutritional businesses following the separation of its research-based pharmaceuticals business into a new company, AbbVie Inc . ( ABBV ), in Jan 2013.

We believe the diversification bodes well for Abbott Labs and should enable the company to counter the challenging business environment as a result of austerity measures undertaken by developed markets in 2013 coupled with weak economic conditions elsewhere.

Abbott Labs currently carries a Zacks Rank #3 (Hold).  Right now, Alere Inc . ( ALR ) and Exactech, Inc. ( EXAC ) look well placed in the medical sector. While Alere carries a Zacks Rank #1 (Strong Buy), Exactech carries a Zacks Rank #2 (Buy).

ABBVIE INC (ABBV): Free Stock Analysis Report

ABBOTT LABS (ABT): Free Stock Analysis Report

ALERE INC (ALR): Free Stock Analysis Report

EXACTECH INC (EXAC): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: ABBV , ABT , ALR , EXAC

More from

Related Videos

Don't Pay Up to Play REITs
Don't Pay Up to Play REITs          



Most Active by Volume

  • $17.62 ▲ 0.51%
  • $25.62 ▲ 1.91%
  • $111.78 ▼ 0.77%
  • $36.37 ▼ 1.76%
  • $47.66 ▲ 0.29%
  • $2.59 ▼ 0.38%
  • $7.34 ▲ 2.37%
  • $8.14 ▲ 6.96%
As of 12/19/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by